Episode

Episode 47 - Marc Lajoie, CEO at Outpace Bio

Podcast: Few & Far Between: How Biotech Gets Built
Published: Dec 31, 2024
Duration seconds: 2905
Processing state: not_requested
Canonical source: https://few-far-between-conversations-about-rare-disease-research.castos.com/episodes/episode-47-marc-lajoie-ceo-at-outpace-bio
Audio: https://dts.podtrac.com/redirect.mp3/episodes.castos.com/6026d270a471b8-76273800/1931877/c1e-o3p3nbvdqz8fmqq3p-kpdmp30mtzj-siytbc.mp3
JSON: /v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-47-marc-lajoie-ceo-at-outpace-bio
Markdown: /podcast/few-far-between-how-biotech-gets-built-4067896/episode-47-marc-lajoie-ceo-at-outpace-bio.md

Actions

POST https://stenobird.com/v1/public/podcasts/few-far-between-how-biotech-gets-built-4067896/episodes/episode-47-marc-lajoie-ceo-at-outpace-bio/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/few-far-between-how-biotech-gets-built-4067896/episode-47-marc-lajoie-ceo-at-outpace-bio.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

"If you bring powerful technology to a problem that is well understood, then you can really make a difference." - Marc Lajoie, CEO at Outpace Bio Welcome to the latest episode of Biorasi's Few & Far Between podcast. Join host Chris O'Brien and guest, Marc Lajoie, as they discuss how de novo proteins can be used to reprogram immune cells. Tune in today!